Müschen Lab
@muschenlab.bsky.social
B-cell dynamics, oncogenic signaling in B-cell malignancies @YaleUniversity.
On this week's cover of Science Signaling. Congratulations to Ruifeng Sun and Jaewoong Lee, who led this effort! Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia | Science Signaling @yaleschoolofmed.bsky.social @yalecancer.bsky.social www.science.org/eprint/ZZKJP...
Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia
PKCδ and CD25 assemble a complex for negative feedback control of tyrosine kinase signaling in acute leukemia cells.
www.science.org
February 10, 2026 at 7:37 PM
On this week's cover of Science Signaling. Congratulations to Ruifeng Sun and Jaewoong Lee, who led this effort! Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia | Science Signaling @yaleschoolofmed.bsky.social @yalecancer.bsky.social www.science.org/eprint/ZZKJP...
EACR - Overactivation of Oncogenic Signalling as a Potential Cancer Treatment Strategy - ecancer ecancer.org/en/conferenc...
EACR - Overactivation of Oncogenic Signalling as a Potential Cancer Treatment Strategy - ecancer
Over the past decade, our understanding of the molecular defects in cancer have been exploited to develop drugs to inhibit oncogenic signalling. While these are
ecancer.org
January 18, 2026 at 1:54 AM
EACR - Overactivation of Oncogenic Signalling as a Potential Cancer Treatment Strategy - ecancer ecancer.org/en/conferenc...
Our last post on X (after 1 year hiatus) is our 1st post here, with Nehir Cosgun's paper: B-catenin promotes cancer growth but B-cell leukemia depends on its degradation. Nehir's paper shows how this dependency could be leveraged for the benefit of patients with B-ALL.👇 nature.com/articles/s43...
January 10, 2026 at 8:02 PM
Our last post on X (after 1 year hiatus) is our 1st post here, with Nehir Cosgun's paper: B-catenin promotes cancer growth but B-cell leukemia depends on its degradation. Nehir's paper shows how this dependency could be leveraged for the benefit of patients with B-ALL.👇 nature.com/articles/s43...